

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

29 Jul 2026

### Assessment of the adjuvant ketogenic diet effect on the therapeutic outcomes of metastatic breast cancer patients

#### Protocol summary

##### Study aim

Assessment of the adjuvant ketogenic diet effect on the therapeutic outcomes of metastatic breast cancer patients

##### Design

This randomized- parallel and open-label clinical trial study (phase 3) will be conducted on 42 metastatic breast cancer patient. Patients will be divided into ketogenic diet and control groups using the block randomization method.

##### Settings and conduct

In this randomized- parallel and open-label clinical trial study, 42 metastatic breast cancer patients referred to the oncology department of Urmia Imam Khomeini hospital will be enrolled. Patients in the intervention group will be received a ketogenic diet in addition to the standard chemotherapy protocol. The standard chemotherapy protocol will be implemented in the control group.

##### Participants/Inclusion and exclusion criteria

In this study, patients over 18 years of age with metastatic breast cancer will be included. Patients with lipid metabolism disorders such as carnitine deficiency, patients with liver failure, metastatic liver tissue more than 50%, a history of gastric and pancreatic surgeries, renal cell carcinoma, and type 1 diabetes will be excluded.

##### Intervention groups

Patients in the intervention group will be received a ketogenic diet in addition to the standard chemotherapy protocol. The standard chemotherapy protocol will be implemented in the control group.

##### Main outcome variables

Primary tumor size and the metastasis; Vascular endothelium growth factor expression (VEGF); Ketone bodies; Serum albumin; CRP; Quality of life

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210919052515N1**

Registration date: **2021-10-22, 1400/07/30**

Registration timing: **prospective**

Last update: **2021-10-22, 1400/07/30**

Update count: **0**

##### Registration date

2021-10-22, 1400/07/30

##### Registrant information

##### Name

Naser Masoudi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 44 3337 9924

##### Email address

masoudi.n@umsu.ac.ir

##### Recruitment status

##### Recruitment complete

##### Funding source

##### Expected recruitment start date

2021-11-22, 1400/09/01

##### Expected recruitment end date

2022-02-20, 1400/12/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  |                                                                                          |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------------------------------------------|--|
| Assessment of the adjuvant ketogenic diet effect on the therapeutic outcomes of metastatic breast cancer patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  | <b>Street address</b><br>Urmia University of Medical Sciences, Resalat Ave, Urmia, Iran. |  |
| <b>Public title</b><br>The ketogenic diet effect in treatment of metastatic breast cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |  | <b>City</b><br>Urmia                                                                     |  |
| <b>Purpose</b><br>Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  | <b>Province</b><br>West Azarbaijan                                                       |  |
| <b>Inclusion/Exclusion criteria</b><br><b>Inclusion criteria:</b><br>Metastatic breast cancer patients Age over 18 years<br><b>Exclusion criteria:</b><br>Lipid metabolism disorders such as carnitine deficiency<br>Patients with liver failure Metastasis more than 50% of liver tissue History of gastric and pancreatic surgeries<br>Renal cell carcinoma Type 1 diabetes                                                                                                                                                                                                                                                                                              |  | <b>Postal code</b><br>5714783734                                                         |  |
| <b>Age</b><br>From <b>18 years</b> old                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  | <b>Approval date</b><br>2021-09-13, 1400/06/22                                           |  |
| <b>Gender</b><br>Female                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |  | <b>Ethics committee reference number</b><br>IR.UMSU.REC.1400.219                         |  |
| <b>Phase</b><br>3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  | <b>Health conditions studied</b>                                                         |  |
| <b>Groups that have been masked</b><br><i>No information</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |  | <b>1</b>                                                                                 |  |
| <b>Sample size</b><br>Target sample size: <b>42</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |  | <b>Description of health condition studied</b><br>Breast cancer                          |  |
| <b>Randomization (investigator's opinion)</b><br>Randomized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  | <b>ICD-10 code</b><br>C50                                                                |  |
| <b>Randomization description</b><br>Patients will be divided into intervention and control groups using the block randomization method. According to the total sample size (42 patients), 7 blocks of 6 will be considered. (A: intervention group and B: control group). so that all possible combinations of AAA BBB will be listed. Then each combination will be given a number of one to seven. A number will be selected randomly for the determination of one of the possible combinations. The randomization process will be continued until the last combination is enrolled. Patients will be divided into two groups according to the order of selected blocks. |  | <b>ICD-10 code description</b><br>Malignant neoplasm of breast                           |  |
| <b>Blinding (investigator's opinion)</b><br>Not blinded                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |  | <b>Primary outcomes</b>                                                                  |  |
| <b>Blinding description</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  | <b>1</b>                                                                                 |  |
| <b>Placebo</b><br>Not used                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |  | <b>Description</b><br>Primary tumor size and metastasis                                  |  |
| <b>Assignment</b><br>Parallel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  | <b>Timepoint</b><br>Before and three months after the intervention                       |  |
| <b>Other design features</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |  | <b>Method of measurement</b><br>With CT scan imaging in millimeters                      |  |
| <b>Secondary Ids</b><br>empty                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  | <b>Secondary outcomes</b>                                                                |  |
| <b>Ethics committees</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  | <b>1</b>                                                                                 |  |
| <b>Ethics committee</b><br><b>Name of ethics committee</b><br>Ethics Committee of Urmia University of Medical Sciences                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  | <b>Description</b><br>Ketone Bodies                                                      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | <b>Timepoint</b><br>Before and three months after the intervention                       |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | <b>Method of measurement</b><br>Ketone meter in blood serum (mM/L)                       |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | <b>2</b>                                                                                 |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | <b>Description</b><br>Vascular endothelium growth factor expression (VEGF)               |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | <b>Timepoint</b><br>Before and three months after the intervention                       |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | <b>Method of measurement</b><br>Blood serum (Pg/mL)                                      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | <b>3</b>                                                                                 |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | <b>Description</b><br>C-Reactive Protein (CRP)                                           |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  | <b>Timepoint</b><br>Before and three months after the intervention                       |  |

**Method of measurement**

Blood serum (mg/L)

**4****Description**

Serum albumin

**Timepoint**

Before and three months after the intervention

**Method of measurement**

Blood serum sample (gr/dl)

**5****Description**

Quality of life

**Timepoint**

Before and three months after the intervention

**Method of measurement**

Breast cancer-specific quality of life questionnaire (QLQ-BR 23)

**Intervention groups****1****Description**

Intervention group: Patients will be received the ketogenic diet for three months in addition to the standard chemotherapy protocol. Manuals of this diet will be provided to patients.

**Category**

Treatment - Other

**2****Description**

Control group: In the control group, only the standard chemotherapy protocol will be implemented for patients.

**Category**

Treatment - Other

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Urmia Imam Khomeini Educational hospital

**Full name of responsible person**

Dr. Naser Masoudi

**Street address**

Imam Khomeini Educational hospital, Ershad Ave,  
Modarress Blvd, Urmia, Iran.

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5715781351

**Phone**

+98 44 3345 9538

**Email**

dr.nasmasoudi@gmail.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Dr. Iraj Mohebbi

**Street address**

Urmia University of Medical Sciences, Resalat Ave,  
Urmia, Iran.

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5714783734

**Phone**

+98 44 3223 1930

**Email**

mohebbi.i@umsu.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Oroumia University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Dr.Naser Masoudi

**Position**

Assistant Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

General Surgery

**Street address**

Imam Khomeini hospital, Ershad Ave, Modarres Blvd,  
Urmia, Iran.

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5715781351

**Phone**

+98 44 3337 9924

**Email**

dr.nasmasoudi@gmail.com

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Dr. Naser Masoudi

**Position**

Assistant professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

General Surgery

**Street address**

Imam Khomeini hospital, Ershad Ave, Modarress Blvd,  
Urmia, Iran.

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5715781351

**Phone**

+98 44 3345 9538

**Email**

dr.nasmasoudi@gmail.com

## Person responsible for updating data

**Contact****Name of organization / entity**

Oroumia University of Medical Sciences

**Full name of responsible person**

Dr. Naser Masuodi

**Position**

Assistant professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

General Surgery

**Street address**

Imam Khomeini hospital, Ershad Ave, Modarress Blvd,  
Urmia, Iran.

**City**

Urmia

**Province**

West Azarbaijan

**Postal code**

5715781351

**Phone**

+98 44 3345 9538

**Email**

dr.nasmasuodi@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

The results will be published as an article

**When the data will become available and for how long**

After the publishing of the article

**To whom data/document is available**

Researchers

**Under which criteria data/document could be used**

as published article

**From where data/document is obtainable**

Corresponding author

**What processes are involved for a request to access data/document**

If necessary through e-mail addresses of the corresponding author in the published article can have access to the data.

**Comments**